William Blair Predicts Weaker Earnings for agilon health

agilon health, inc. (NYSE:AGL) – Equities researchers at William Blair decreased their Q2 2025 earnings estimates for agilon health in a report released on Tuesday, February 25th. William Blair analyst R. Daniels now expects that the company will post earnings per share of ($0.04) for the quarter, down from their previous forecast of ($0.02). William Blair has a “Market Perform” rating on the stock. The consensus estimate for agilon health’s current full-year earnings is ($0.59) per share. William Blair also issued estimates for agilon health’s Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.26) EPS and FY2026 earnings at ($0.17) EPS.

Several other equities analysts have also recently commented on the company. Macquarie began coverage on agilon health in a research note on Monday, December 16th. They set a “neutral” rating and a $3.00 target price for the company. Needham & Company LLC reiterated a “hold” rating on shares of agilon health in a research note on Wednesday. Citigroup raised shares of agilon health from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $1.75 to $2.25 in a report on Friday, January 10th. Barclays cut their target price on shares of agilon health from $5.00 to $2.00 and set an “underweight” rating on the stock in a research note on Monday, November 11th. Finally, Stifel Nicolaus lifted their price target on agilon health from $2.00 to $3.00 and gave the stock a “hold” rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, agilon health currently has an average rating of “Hold” and an average price target of $3.95.

agilon health Price Performance

Shares of AGL stock opened at $3.35 on Friday. agilon health has a twelve month low of $1.50 and a twelve month high of $7.73. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $1.38 billion, a PE ratio of -3.56 and a beta of 0.66. The firm has a fifty day simple moving average of $2.94 and a 200-day simple moving average of $3.04.

Hedge Funds Weigh In On agilon health

Several large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in agilon health by 326.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,415,419 shares of the company’s stock worth $5,563,000 after purchasing an additional 1,083,492 shares during the last quarter. Inspire Investing LLC boosted its position in shares of agilon health by 106.6% during the fourth quarter. Inspire Investing LLC now owns 217,550 shares of the company’s stock worth $413,000 after purchasing an additional 112,241 shares in the last quarter. Citigroup Inc. grew its stake in agilon health by 2,251.5% in the third quarter. Citigroup Inc. now owns 2,028,246 shares of the company’s stock valued at $7,971,000 after acquiring an additional 1,941,993 shares during the period. Geode Capital Management LLC lifted its holdings in shares of agilon health by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 6,893,517 shares of the company’s stock valued at $27,097,000 after purchasing an additional 84,889 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of agilon health in the fourth quarter valued at approximately $97,000.

Insider Activity at agilon health

In other agilon health news, Director John William Wulf purchased 45,000 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was acquired at an average cost of $2.18 per share, with a total value of $98,100.00. Following the completion of the acquisition, the director now directly owns 206,133 shares of the company’s stock, valued at $449,369.94. This represents a 27.93 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Karen Mcloughlin bought 25,000 shares of agilon health stock in a transaction dated Friday, December 13th. The shares were bought at an average price of $2.20 per share, for a total transaction of $55,000.00. Following the completion of the transaction, the director now directly owns 73,166 shares of the company’s stock, valued at $160,965.20. This represents a 51.90 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 77,500 shares of company stock worth $169,600 in the last ninety days. 3.20% of the stock is currently owned by insiders.

About agilon health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.